Anti-CD19-CAR-T cells is named as an intervention in 4 current clinical trials in our China register. 2 are recruiting patients now. The most common phase is Phase EARLY_PHASE1. The sponsor with the most trials is Shanghai Tongji Hospital, Tongji University School of Medicine (1). The most-studied condition is B Cell Malignancies.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients.
NCT06375161 · ClinicalTrials.gov ↗ · B Cell Malignancies
|
Phase EARLY_PHASE1 | Recruiting | Shanghai Tongji Hospital, Tongji University School of Medicine | China |
|
A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy
NCT06756321 · ClinicalTrials.gov ↗ · Relapsed/refractory Lymphoma, Relapsed/Refractory Leukemia
|
Phase EARLY_PHASE1 | Recruiting | Affiliated Hospital of Nantong University | China |
|
The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases
NCT06420154 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis
|
Phase EARLY_PHASE1 | Not yet open | First Affiliated Hospital of Wenzhou Medical University | China |
|
Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus
NCT06222853 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus, CAR-T Cell Therapy
|
Phase 1 | Active, closed | The Children's Hospital of Zhejiang University School of Medicine | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Shanghai Tongji Hospital, Tongji University School of Medicine | 1 |
| Affiliated Hospital of Nantong University | 1 |
| First Affiliated Hospital of Wenzhou Medical University | 1 |
| The Children's Hospital of Zhejiang University School of Medicine | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 4 | 2 |
A trial with sites in more than one country appears in each of those registers.
4 current trials in our China register name Anti-CD19-CAR-T cells as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 4 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Shanghai Tongji Hospital, Tongji University School of Medicine (1), Affiliated Hospital of Nantong University (1), First Affiliated Hospital of Wenzhou Medical University (1) and The Children's Hospital of Zhejiang University School of Medicine (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Anti-CD19-CAR-T cells works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Anti-CD19-CAR-T cells works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Anti-CD19-CAR-T cells (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.